logo-loader
viewFutura Medical PLC

Futura Medical on track with lead drug

The update in erectile dysfunction treatment MED2005 was provided alongside interim results

Futura Medical PLC -
The gel has a number of potential advantages over the current array of pills

Futura Medical PLC (LON:FUM) chief executive James Barder said the company’s team is speaking to key opinion leaders in the field of erectile dysfunction ahead of publishing headline data on MED2005 later this year.

The company’s drug candidate is a fast-acting gel that eliminates some of the common side-effects of the current pill-based treatments.

Safety, dosing and efficacy are currently being assessed as part of European phase III clinical trial.

In an update alongside the company’s interim results, Barder said most of the men taking part in the double-blind study had elected to continue into the open-label safety stage during which all patients are on the highest dose of MED2005.

The gel is one of a number of products being developed by Futura, whose technology transfers drugs through the skin barrier.

It is partnered to take a pain and inflammation product to the market called TPR100 and is currently in communication with the UK regulator to clear up queries around it. It should have a response for the MHRA by the first quarter of next year, investors were told.

It has also teamed up to develop its technology to deliver CBD, the non-psychoactive element of cannabis that is linked with pain relief as well as being used to combat stress and anxiety.

The financials revealed the company had £5.63mln cash as at the end of June, while it picked up a £1.36mln research and development credit in August.

As is common for company’s at this formative stage of their development, Futura was loss-making - to the tune of £4.46mln.

Quick facts: Futura Medical PLC

Price: 11.125 GBX

AIM:FUM
Market: AIM
Market Cap: £22.77 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Futura Medical sees 'potentially quicker route to market' for its erectile...

Futura Medical PLC's (LON:FUM) executive director and head of R&D Ken James speaks to Proactive London's Andrew Scott following the read-out from the phase III clinical trial of its erectile dysfunction gel. James says while MED2005 showed strong efficacy, excellent safety and rapid speed...

on 11/12/19

RNS

GM Statement

1 day, 16 hours ago

Second Price Monitoring Extn

1 week, 5 days ago

Price Monitoring Extension

1 week, 5 days ago

Result of Fundraising

3 weeks, 6 days ago

Second Price Monitoring Extn

4 weeks, 2 days ago

Price Monitoring Extension

4 weeks, 2 days ago

PrimaryBid Offer

4 weeks, 2 days ago

2 min read